The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

Since the acquisition of the Dbait technology last February,
Onxeo has launched an ambitious clinical development program for AsiDNA, a first-in-class product derived directly from this technology

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that Doctor Marie Dutreix has received the Lazorthes Prize, awarded by the prestigious French Academy of Sciences in Paris, for her research on the Dbait technology. AsiDNA™, a molecule derived directly from the Dbait concept, breaks the cycle of tumor DNA repair by inducing the accumulation of damage in the DNA and cell death in tumor cells, while sparing healthy cells.

Since acquiring the Dbait technology in February, Onxeo has initiated an  ambitious development program in order to realize the strong potential of AsiDNA™ in monotherapy or in combination with other anti-cancer therapies. A first Phase I clinical trial in patients with metastatic melanoma demonstrated the good tolerance and safety of AsiDNA™ in intra-tumoral and subcutaneous administration combined with radiotherapy. This Phase I study also revealed some very promising signs of efficacy of the molecule used in combination with radiotherapy. Onxeo has decided to continue to develop this drug for systemic administration and evaluate the safety and level of tolerance, in monotherapy or in combination with other treatments, when used in various types of solid tumors. Therefore, a new Phase I clinical trial will begin in 2017 following regulatory toxicology tests.

At the same time, Onxeo has published the results of preclinical research studies in Clinical Cancer Research1, which demonstrate the synergistic effect of AsiDNA when combined with several products from the PARP (Poly ADP-Ribose Polymerase) inhibitor class. These new data have confirmed the advantages of AsiDNA™ compared to PARP inhibitors alone, as well as the benefits of combining the two DNA repair inhibitors.

Judith Greciet, CEO of Onxeo, said: “We are delighted that Dr. Dutreix has been recognised and rewarded by the members of the prestigious French Academy of Sciences for her research work in the domain of DNA repair, which generated the breakthrough innovative technology DBAIT and its first application AsiDNA™. Dr. Dutreix is still closely involved as a consultant in the development of  AsiDNA. This technology positions Onxeo at the forefront of medical research with a promising and innovative therapeutic approach for cancer patients, while providing strong value-creation for our shareholders“.

1 – « Drug Driven Synthetic Lethality: bypassing tumor cell genetics with a combination of Dbait and PARP inhibitors », published the “Clinical Cancer Research” in September 2016.

Download PDF